|
Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices. |
|
|
Employment - Illumina; IntegraConnect |
Stock and Other Ownership Interests - Illumina |
Consulting or Advisory Role - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Patent title: Systems and methods for outlier significance assessment Patent date Filed: Nov 3, 2016 IP-1417-PRV; Patent title: Systems and methods for outlier significance assessment Patent date Filed: Nov 3, 2016 IP-1417-PRV |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Guardant Health |
|
|
No Relationships to Disclose |
|
|
Employment - Guardant Health |
Stock and Other Ownership Interests - Guardant Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Guardant Health; Trovagene |
Stock and Other Ownership Interests - Guardant Health; Trovagene |
|
|
Employment - Guardant Health; Veracyte |
Leadership - Biolase; Guardant Health |
Stock and Other Ownership Interests - Biolase; Forward; Guardant Health |
Speakers' Bureau - Forward |
Research Funding - Guardant Health |
|
|
Employment - IntegraConnect |
Consulting or Advisory Role - MD Anderson Cancer Center |
|
|
Employment - IntegraConnect |
Stock and Other Ownership Interests - Celgene |